Xpert MTB/RIF assay

From Aaushi
Jump to navigation Jump to search

Indications

Clinical significance

Procedure

Notes

More general terms

References

  1. 1.0 1.1 Physician's First Watch, Julu 29, 2013 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
    FDA MedWatch. July 25, 2013 FDA permits marketing of first U.S. test labeled for simultaneous detection of tuberculosis bacteria and resistance to the antibiotic rifampin. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm362602.htm
  2. 2.0 2.1 Theron G et al Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. The Lancet, Early Online Publication, 28 October 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24176144 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62073-5/abstract